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ABSTRACT
Background. The number of people with diabetes 
increases every year, both in Poland and worldwide. 
In Poland, the exact number is not known, and the lat-
est data comes from 2014. The aim of the study was 
to assess basic epidemiological indicators regarding 
diabetes in Poland in 2014–2017.
Material and methods. Division into types of diabetes 
and other analyzes was carried out on the basis of data 
prepared by a team of experts and employees of the 
Department of Analysis and Strategy of the Ministry of 
Health. The NHF databases were used, concerning real-
ized medical interventions and refunded prescriptions.
Results. The number of people with diabetes in Poland 
in 2014 was 2.113 million (1.167 million women and 
0.946 million men). This number increased in subse-
quent years and in 2017 amounted to 2.533 million 
(1.408 million women and 1.124 million men), which 
constituted 6.58% of the population. Using the adopt-
ed methodology, the number of patients in whom the 
type of diabetes could not be determined was large 
and ranged from 39.57% to 32.75% in individual years.
Conclusions. Diabetes prevalence in Poland is in-
creasing. The adopted methodological assumptions 
regarding the division criteria for type 2 and type 1 
diabetes do not allow an accurate determination of 
the epidemiology of diabetes by type (incidence rate 
and morbidity), but they allow to determine “specific” 
subpopulations of patients with a given type of dis-
ease. (Clin Diabetol 2020; 9; 5: 279–285)
Key words: diabetes, morbidity, Poland, National 
Health Fund
Introduction
Diabetes is a group of metabolic disorders chara-
cterized by chronic hyperglycaemia which leads to 
damage, dysfunction, and failure of various organs [1]. 
The European Parliament declaration of Apr 16, 2006, 
and the United Nations resolution of Dec 20, 2006 both 
declared diabetes the first non-infectious epidemic 
disease that poses a worldwide public health threat [2].
In the 2016 World Health Organization (WHO) 
report on diabetes, the number of patients with this 
disease worldwide in 2014 was estimated at 422 mil-
lion [3]. As the number of patients with diabetes in 
1980 was 108 million, it can be concluded that the 
global prevalence of diabetes increased nearly 4-fold 
over 34 years. Experts of the International Diabetes 
Federation (IDF) predict that the number of patients 
with diabetes worldwide, estimated at 463 million in 
2019, will increase to 700 million in 2045, translating 
to a 51% increase over the next 25 years [4, 5]. It is thus 
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necessary to improve organization of care for diabetic 
patients, the directions of which were set for the first 
time at the international level under the auspices of 
WHO and IDF in the 1989 St. Vincent Declaration [6].
Appropriate planning of healthcare services must 
be based on reliable epidemiological data which are 
also of significant prognostic importance. However, 
the number of patients with diabetes in Poland has 
not been precisely estimated, and there is no national 
Polish population registry of diabetic patients. The 
data on the scope of diabetes problem in Poland come 
from studies performed in various age groups, specific 
regions, or focusing on other health problems that also 
provided information on diabetes. Most commonly 
cited studies such as the regional Pol-MONICA study 
and multicentre national WOBASZ II and NATPOL 2011 
surveys evaluated cardiovascular disease risk factors 
[7–9]. The POLSENIOR study evaluated the health sta-
tus of the population above 65 years of age [10]. Data 
provided by WHO and IDF are based on information 
collected from specific countries, and if such data are 
unavailable, these are only estimates based on data 
from countries at a similar level of development and 
with similar demographic characteristics of the popula-
tion [5]. This necessitates the search for other reliable 
sources of information that would allow defining the 
morbidity due to diabetes in Poland. In the recent 
years, such opportunities have been provided by the 
databases of contracted health services and medica-
tion reimbursement run by the National Health Fund 
(Narodowy Fundusz Zdrowia, NFZ) which is the only 
public healthcare payer in Poland. Such an analysis was 
performed for years 2010–2014 [11]. Another analysis 
was performed for the year 2013 by the expert panel of 
the Polish Academy of Sciences, convened to evaluate 
the epidemiology of diabetes in Poland and the quality 
of public reporting in this area. Data sources included 
NFZ databases, results of the ReceptoMetr and NATPOL 
2011 studies, and regional registries of children with 
diabetes [12].
Since 2014, with the introduction of the Maps 
of Health Needs in Poland, experts and employees of 
the Department of Analyses and Strategy of the Polish 
Ministry of Health perform analyses for the purpose of 
forecasting and planning healthcare related to specific 
health problems [13]. As the most recent analyses 
on the epidemiology of diabetes were performed in 
2014, the aim of the present study was to evaluate 
basic epidemiological indices of diabetes in Poland in 
2014–2017 based on the analyses performed by the 
experts and employees of the Department of Analyses 
and Strategy of the Polish Ministry of Health using the 
NFZ database.
Methods
The present study was a part of the project en-
titled: Maps of Health Needs: Database of System 
and Implementation Analyses (Polish title: Mapy 
potrzeb zdrowotnych: Baza Analiz Systemowych i 
Wdrożeniowych). The project was supported by the 
European Union (European Social Fund, Operational 
Programme Knowledge Education Development) and 
undertaken by the Department of Analyses and Strategy 
at the Polish Ministry of Health (Departament Analiz i 
Strategii Ministerstwa Zdrowia w Polsce; http://www.
mpz.mz.gov.pl).
The system of healthcare in Poland is based on an 
insurance model, providing the citizens with an equal 
access to health care services financed from public 
funds. The institutional healthcare payer is NFZ. It 
provides funds for healthcare services and reimburse-
ment of medications, nutritional products and medical 
products from the collected obligatory health insurance 
premiums.
Healthcare providers that signed an agreement 
with NFZ regarding the provision of outpatient and 
inpatient healthcare services are obliged to run an 
electronical registry of these services. Data collected 
in these healthcare service registries include patient 
identifying data and the International Statistical Clas-
sification of Diseases and Related Health Problems 
(ICD-10) disease codes for a given service. These data 
are then transferred to NFZ.
Pharmacies collect data on filled prescriptions and 
transfer these data to NFZ. The scope of data on the 
turnover of medications, special nutritional products, 
and medical products subject to reimbursement in-
cludes the patient identifying number, and the code 
number (European Article Numbering, EAN) of a medi-
cation, special nutritional product, or medical product.
Sources of data
The analyses for the years 2014–2017 were per-
formed using the following NFZ databases:
 — healthcare service claim database;
 — filled and reimbursed prescription database.
Preparation of the baseline dataset
The baseline dataset of persons with diabetes was 
defined in the following way:
 — patients with the following ICD-10 codes for 
diabetes reported to NFZ as the primary or 
concomitant diagnosis were included: E10 — 
insulin-dependent diabetes mellitus, E11 — 
non-insulin-dependent diabetes mellitus, E12 
— malnutrition-related diabetes mellitus, E13 — 
other specified diabetes mellitus, E14 — unspeci-
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fied diabetes mellitus [11]. For clarity, three-digit 
ICD-10 codes were used, while in fact full codes 
(up to five digits) were taken into account;
 — it was assumed that patients with diabetes should 
have it reported at least once as the primary diag-
nosis during their medical care, and patients who 
did not fulfil this criterion were excluded;
 — patients with a reported code for cystic fibrosis 
were removed from the dataset;
 — gestational diabetes and diabetes during preg-
nancy were not included due to their nature and 
the fact that they are covered by the O24 code 
together with various types of pre-pregnancy dia-
betes;
 — finally, it was checked what antidiabetic medica-
tions and medical products (glucose meter test 
strips) were prescribed to patients in the dataset 
defined as above. Patients who filled prescriptions 
for oral drugs but not for glucose meter test strips 
were removed from the dataset as these persons 
might have had prediabetes (as reimbursement 
for glucose meter test strips does not include per-
sons with prediabetes).
The algorithm for dividing the baseline  
dataset into specific diabetes types
Due to the fact that based on the ICD-10 codes 
reflecting diabetes management, the diabetes type 
according to the WHO etiological classification can-
not be determined, the algorithm for dividing the 
baseline dataset into specific diabetes types, based 
on the assumption that major diabetes types are re-
lated to age. The diabetes types were defined within 
yearly data volumes, separately based on healthcare 
service claims and medications. These results were 
then integrated and the diabetes type was finally 
assigned to a given patient in a given year. The clas-
sification based on healthcare service claims is shown 
in Table 1.
If a patient was assigned both E10 and E11 codes, 
the diabetes type was determined based on the major-
ity rule at 90% of all diagnoses reported for a given 
patient in a given year.
For medications, there was no need to make spe-
cific assumptions based on the patient’s age, as medi-
cations define the type of diabetes. The classification 
based on medications is shown in Table 2.
After the diabetes type was defined separately 
based on healthcare service claims and medications, 
these two categorizations were compared to each 
other. In some cases, the type defined based on the 
healthcare service claim database was different from 
the one assigned based on the medications. In these 
situations, diabetes type was defined based on the 
medications purchased by the patient. If despite the 
above assumptions the patient still could not be clearly 
assigned a diabetes type, he was categorized as unde-
termined diabetes type.
The age distribution of patients with diabetes type 1 
and type 2 was also analysed. The peak incidence of 
diabetes type 1 is in the juvenile period and thus it was 
assumed that patients diagnosed with diabetes type 1 
after the age of 40 were not appropriately categorized 
and were excluded from the group of patients with 
diabetes type 1.
Results
The number of subjects with diabetes in Poland 
in 2014 was 2.113 million (1.167 million women and 
0.946 million men). This number increased in the sub-
sequent years, reaching 2.533 million in 2017 (1.408 
million women and 1.124 million men). Figure 1 shows 
Table 1. Classification of diabetes based on healthcare service claims
Children (below 18 years of age) Adults
Type 1 Only E10; E10 and E14 together Only E10
Type 2 Only E11; E11 and E14 together Only E11
Undetermined Cannot be clearly determined based on ICD-10 codes Cannot be clearly determined based on ICD-10 codes
Table 2. Classification of diabetes based on the filled prescription database
Type 1 Patient fills prescriptions for insulin or glucagon and glucose meter test strips, but not for oral medications
Type 2 Patient fills prescriptions for oral medications and glucose meter test strips, but not for insulin
Prediabetes Patient fills prescriptions for oral medications but not glucose meter test strips (persons with prediabetes are 
not entitled for reimbursement of glucose meter test strips)
Undetermined None of the above conditions is met but the patient filled prescriptions for any antidiabetic medications
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million in 2014 to 2.533 million in 2017. The increas-
ing prevalence of diabetes, as already noted in the 
introduction, has been observed worldwide and 
was also shown in our previous study covering the 
2010–2014 period [11]. The design of the present 
study, however, was different. In the previous, study, 
based on the number of filled prescription, the number 
of patients with diabetes in 2014 was 2.34 million, 
somewhat higher compared to the present estimates. 
This difference is likely due to the fact that in the 
present study, we attempted to exclude patients with 
prediabetes (who did not fill prescriptions for glucose 
meter test strips).
In contrast, Topór-Mądry et al. [12] estimated the 
number of patients with diabetes (both diagnosed 
and undiagnosed) in Poland at 2.68 million in 2013. 
It should be noted, however, that our studies did not 
include undiagnosed diabetes. The number of patients 
with diabetes in Poland as reported in the IDF Diabetes 
Atlas 2019 is 2.34 million, but these estimates are for 
Table 3. Prevalence and incidence of diabetes in Poland in 2014–2017
Year Population of Poland in  
millions according to GUS




New cases  
in thousands
2014 38.48 2.113 5.48% 178.17
2015 38.44 2.261 5.88% 218.32
2016 38.43 2.404 6.25% 224.05
2017 38.43 2.533 6.58% 215.61
GUS — Central Statistical Office of Poland (Główny Urząd Statystyczny)




























Figure 1. Number of persons with diabetes in Poland in 
2014–2017
Table 4. Number of patients with diabetes (overall and specific types) in 2014–2017
2014 2015 2016 2017
Number of patients with diabetes 2,113,099 2,261,885 2,404,426 2,532,891
Type 1 174,547 (8.26%) 166,574 (7.36%) 161,314 (6.71%) 157,188 (6.21%)
Type 2 1,102,320 (52.17%) 1,255,190 (55.49%) 1,406,684 (58.5%) 1,546,156 (61.04%)
Undetermined type 836,232 (39.57%) 840,121 (37.14%) 836,428 (34.79%) 829,547 (32.75%)
Table 5. Mean patient age at the time of the diagnosis of 
diabetes in 2014–2017
Year Mean age at the time  
of diagnosis  
— diabetes type 1
Mean age at the time  
of diagnosis  





the number of subjects with diabetes in subsequent 
years, overall and in relation to gender, and the data 
on prevalence and incidence are shown in Table 3.
The proportion of patients with diabetes type 1 
and 2 in the overall number of subjects with diabetes in 
2014–2017 is shown in Table 4. Table 5 shows the mean 
patient age at the time of the diagnosis of diabetes in 
subsequent years.
The distribution of age in patients with diabetes 
type 1 at the time of the diagnosis of diabetes in sub-
sequent years is shown in Figure 2. The distribution of 
age in patients with diabetes type 2 at the time of the 
diagnosis of diabetes in subsequent years is shown in 
Figure 3.
Discussion
In our analysis, we showed that the number of 
patients with diabetes in Poland increased from 2.113 
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the population aged 20–79 years, and the 95% confi-
dence interval is very wide (1.70–6.31 million).
As indicated by the above, the studies on the 
epidemiology of diabetes in Poland are not entirely 
comparable as they were performed in various regions, 
were targeted on patients from various age groups, 
focused on various types and aspects of diabetes, and 
differed in methodology. The same applies to com-
parisons with studies in other countries or regions. 
With these caveats in mind, it can be concluded that 
based on our data, the prevalence of diabetes in Poland 
in somewhat lower compared to the United States 
(where, in 2013–2016, persons with diagnosed diabe-





















































































































Figure 3. Distribution of age in patients with diabetes type 2 at the time of the diagnosis of diabetes in 2014–2017
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years of age) [14], and somewhat lower compared to 
Europe (where the mean prevalence of diabetes among 
subjects aged 20–79 years in 2019 was 8.9%) [4]. In 
addition, these differences appeared despite the fact 
that our analysis included the whole Polish population, 
while the above cited reports were based on selected 
specific age groups.
The increasing prevalence of diabetes results, at 
least in part, from an increase in the number of obese 
subjects related to the “western” lifestyle (lack of exer-
cise, inappropriate diet). As shown in Table 3, however, 
the dynamics of the increase in diabetes prevalence 
differed from the dynamics of diabetes incidence. 
The increase in diabetes prevalence was quite marked 
despite a relatively stable incidence. Such a trend was 
noted in at least some other studies. In a recently pub-
lished systematic review of population studies on the 
incidence of diabetes overall or diabetes type 2 world-
wide, it was found that the incidence of diabetes was 
stable in 30% of the studied populations, and showed 
a downward trend in 36% of the studied populations 
[15]. This increase in the prevalence despite a stable 
incidence may be due to increasing life expectancy and 
improving diabetes care [4] which leads to an increased 
survival among diabetic patients.
Diabetes type 2 accounts for about 90% of all 
diabetes cases [16, 17]. In our study, however, the 
proportion of patients with diabetes type 2 was mark-
edly lower, which is most likely due to the fact that our 
assumptions regarding the categorization into diabetes 
type 2 and type 1 were specific but not sensitive for 
diabetes type 2. In other words, many patients could 
not be assigned a particular diabetes type based on 
the chosen criteria but the likelihood that a patient 
was assigned a wrong diabetes type was relatively low.
Table 4 shows a decreasing number of patients 
with diabetes type 1 in subsequent years. Taking into 
account the observed increase in the incidence of 
diabetes among children aged 0–14 years in most 
European countries in 1989–2013 (the mean annual 
increase in incidence was 3.4%, including 6.6% in 
Katowice in Poland) [18], it seems that the overall 
number of patients with this type of diabetes might 
be expected to increase. It should be noted, however, 
that out study dealt with the general Polish population 
and not specific age groups.
Diabetes type 1 manifests mostly in children but 
may occur in all age groups (in the United Kingdom, 
diabetes type 1 accounts for 4% of diabetes cases 
diagnosed above 30 years of age) [19]. The mean age 
at the time of the diagnosis of diabetes type 1 in our 
study was 20 to 22 years in various calendar years. 
Distribution of age at the time of diagnosis shows two 
incidence peaks, one at childhood and the other one 
about 25–30 years of age. Studies show that every 
year, more cases of diabetes type 1 occur in adults 
than in adolescents [20]. A study performed in the 
United States showed an increase in the incidence of 
diabetes type 1 at 10–14 years of age, followed by 
a decrease in the incidence and later a rising trend 
since the age of 40. Similarly, an increase in the 
incidence at 10–14 years of age followed by a reduc-
tion and then gradual increase in the incidence was 
observed in a study based on the population registry 
in Turin, Italy [21]. In studies performed in Sweden, 
the first increase in the incidence was observed at 
0–9 years and the other one at 50–80 years [22]. 
These results differ somewhat from our findings but 
it should be noted that one methodological assump-
tion of our study was to exclude diabetes type 1 
diagnoses made after 40 years of age.
A limitation of our study was its retrospective 
nature. In addition, these results only refer to the 
diagnosed diabetes, and it should be remembered 
that diabetes remains undiagnosed in about 30% of 
patients. In addition, available data did not allow clear 
determination of the diabetes type in some patients. A 
valuable information that would help identify patients 
with diabetes type 1 would be to know which patients 
in the baseline dataset were treated using an insulin 
pump. However, we did not have an access to such 
information at the time when the study algorithm 
was developed. 
Conclusions
The prevalence of diabetes in Poland is increas-
ing. In 2017, the prevalence of diabetes in the Polish 
population was 6.58%. The adopted methodological 
assumptions regarding the criteria for distinguishing 
between diabetes type 2 and type 1 do not allow an 
accurate determination of the epidemiology of diabe-
tes by type (incidence and prevalence) but they allow 
determining “specific” subpopulations of patients 
with a given type of disease. Our data will allow an 
analysis of the rates of complications and deaths in 
such groups.
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